V. de Lédinghen

发表

Segmented 5 versus nonsegmented flow quantitation: comparison of portal vein flow measurements.

E. Laffon, R. Lecesne, V. de Lédinghen, 1999, Investigative radiology.

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

V. de Lédinghen, P. Couzigou, B. le Bail, 2005, Gastroenterology.

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C

Christos Christidis, M. Ziol, V. de Lédinghen, 2005, Hepatology.

Hepatitis C virus prevention and care for drug injectors: the French approach

V. de Lédinghen, M. Jauffret-Roustide, D. Dhumeaux, 2018, Hepatology, Medicine and Policy.

EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)

V. de Lédinghen, J. Bamber, G. Ferraioli, 2017, Ultraschall in der Medizin - European Journal of Ultrasound.

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study

V. de Lédinghen, P. Couzigou, B. le Bail, 2005, Gut.

Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases

Laurent Castera, M. Ziol, V. de Lédinghen, 2006, Hepatology.

Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC

M. Ziol, V. de Lédinghen, P. Marcellin, 2006, Hepatology.

Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients.

M. Ziol, V. de Lédinghen, P. Marcellin, 2007, Journal of hepatology.

Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

V. de Lédinghen, J. Foucher, N. Salles, 2009, Gastroenterologie clinique et biologique.

The combination of a blood test and Fibroscan improves the non‐invasive diagnosis of liver fibrosis

V. de Lédinghen, F. Oberti, P. Calès, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.

V. de Lédinghen, P. Couzigou, F. Roudot-thoraval, 2009, Journal of hepatology.

Non‐invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B

Pierre Bedossa, M. Ziol, V. de Lédinghen, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

Julien Vergniol, V. Wong, V. de Lédinghen, 2010, Hepatology.

Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan®.

Julien Vergniol, Michel Montaudon, François Laurent, 2014, Journal of hepatology.

Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy

Julien Vergniol, Christophe Aubé, V. de Lédinghen, 2016, Hepatology.

Assessment of Liver Disease Progression in Cystic Fibrosis Using Transient Elastography

V. de Lédinghen, E. Frison, R. Enaud, 2017, Journal of pediatric gastroenterology and nutrition.

Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis

Ioan Sporea, Thomas Deffieux, Eva Herrmann, 2017, Hepatology.

Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease

V. de Lédinghen, C. Strassburg, M. Ronot, 2021, Gut.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF CHRONIC INFECTION WITH HEPATITIS B VIRUS.

V. de Lédinghen, T. Asselah, X. Causse, 2021, Clinics and research in hepatology and gastroenterology.

Transient Versus Two‐Dimensional Shear‐Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD

V. de Lédinghen, C. Canivet, C. Aubé, 2020, Hepatology.

A cholestatic pattern predicts major liver‐related outcomes in patients with non‐alcoholic fatty liver disease

V. Wong, V. de Lédinghen, G. Sebastiani, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease.

V. de Lédinghen, G. Sebastiani, C. Camma', 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab

V. de Lédinghen, D. Laharie, V. Ledinghen, 2011, Alimentary pharmacology & therapeutics.

Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection.

V. de Lédinghen, P. Couzigou, F. Penin, 2003, The Journal of infectious diseases.

Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

V. de Lédinghen, F. Zerbib, J. Pellegrin, 2010, Journal of hepatology.

Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.

V. de Lédinghen, D. Samuel, J. Dumortier, 2019, Journal of hepatology.

Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination?

V. de Lédinghen, C. Aubé, F. Oberti, 2017, Alimentary pharmacology & therapeutics.

A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases

V. de Lédinghen, B. le Bail, P. Calès, 2017, Journal of clinical gastroenterology.

Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive

V. de Lédinghen, F. Oberti, P. Calès, 2012, Hepatology.

Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.

V. de Lédinghen, Y. Bacq, F. Oberti, 2008, Gastroenterologie clinique et biologique.

Transient elastography (FibroScan).

V. de Lédinghen, J. Vergniol, 2008, Gastroenterologie clinique et biologique.

Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.

V. de Lédinghen, C. Camma', E. Bugianesi, 2019, The American journal of gastroenterology.

Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors

V. de Lédinghen, J. Zucman‐Rossi, T. Asselah, 2022, JHEP reports : innovation in hepatology.

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

V. de Lédinghen, P. Couzigou, H. Fleury, 2002, Journal of hepatology.

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

V. de Lédinghen, P. Couzigou, H. Fleury, 2002, Journal of Hepatology.

ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.

V. de Lédinghen, Y. Ngo, D. Thabut, 2010, Gastroenterologie clinique et biologique.

Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients.

V. de Lédinghen, C. Quereda, J. Macías, 2008, Journal of hepatology.

Should a liver biopsy be done in patients with subclinical chronically elevated transaminases?

V. de Lédinghen, P. Couzigou, M. Amouretti, 2004, European journal of gastroenterology & hepatology.

The burden of NAFLD in type 2 diabetic subjects from the general population: A Nationwide population‐based follow‐up study (NASHCO)

V. de Lédinghen, M. Zins, M. Goldberg, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study.

V. de Lédinghen, X. Causse, B. le Bail, 2006, Journal of hepatology.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF BENIGN LIVER TUMOURS.

V. de Lédinghen, V. Paradis, J. Calderaro, 2021, Clinics and research in hepatology and gastroenterology.

Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection

V. de Lédinghen, P. Couzigou, A. Fontanellas, 1998, Hepatology.

Safety of sofosbuvir‐based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study

V. de Lédinghen, D. Samuel, J. Dumortier, 2018, Alimentary pharmacology & therapeutics.

Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

V. de Lédinghen, P. Dieudé, V. Devauchelle-Pensec, 2021, Joint bone spine.

Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C

V. de Lédinghen, Y. Bacq, G. Hunault, 2008, Liver international : official journal of the International Association for the Study of the Liver.

Comparison of screening strategies with two new tests to score and diagnose varices needing treatment.

V. de Lédinghen, C. Vitellius, P. Nahon, 2022, Clinics and research in hepatology and gastroenterology.

Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder‐relapser hepatitis C patients: a prospective multicentre randomized controlled study

V. de Lédinghen, P. Couzigou, G. Botti, 2003, Journal of viral hepatitis.

Hepatic porphyrin concentration and uroporphyrinogen decarboxylase activity in hepatitis C virus infection

V. de Lédinghen, P. Couzigou, A. Fontanellas, 2001 .

Hepatic porphyrin concentration and uroporphyrinogen decarboxylase activity in hepatitis C virus infection.

V. de Lédinghen, P. Couzigou, A. Fontanellas, 2001, Journal of viral hepatitis.

Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.

V. de Lédinghen, G. Markakis, S. Mueller, 2020, Journal of hepatology.

External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B

V. de Lédinghen, D. Thabut, F. Carrat, 2022, Gastro Hep Advances.

Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

V. de Lédinghen, Y. Ngo, M. Rudler, 2014, Journal of hepatology.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.

V. de Lédinghen, P. Marcellin, D. Thabut, 2019, Gastroenterology.

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

V. de Lédinghen, P. Marcellin, F. Carrat, 2014, Gastroenterology.

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

V. de Lédinghen, P. Marcellin, F. Carrat, 2013, Journal of hepatology.

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort

V. de Lédinghen, F. Dabis, T. Allègre, 2017, Journal of acquired immune deficiency syndromes.

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

V. de Lédinghen, P. Angus, K. Reddy, 2015, JAMA.

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

V. de Lédinghen, P. Marcellin, F. Zoulim, 2015, The Lancet. Infectious diseases.

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.

V. de Lédinghen, G. Everson, S. Zeuzem, 2015, Journal of hepatology.

Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C

V. de Lédinghen, P. Couzigou, A. Constant, 2006, Journal of viral hepatitis.

Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

V. de Lédinghen, T. Asselah, F. Ziegler, 2012, Journal of hepatology.

IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study

V. de Lédinghen, A. Mangia, G. Bakalos, 2016, SpringerPlus.

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences

V. de Lédinghen, P. Marcellin, Y. Yazdanpanah, 2017, Alimentary pharmacology & therapeutics.

Sofosbuvir‐based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation

V. de Lédinghen, D. Samuel, J. Dumortier, 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

M. Manns, V. de Lédinghen, E. Schiff, 2017, The New England journal of medicine.

HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa

V. de Lédinghen, F. Dabis, J. Tine, 2016, BMC Infectious Diseases.

Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis

V. de Lédinghen, E. Asante-Appiah, T. Asselah, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Reply to: "New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?".

V. de Lédinghen, C. Cassinotto, 2015, Journal of hepatology.

Transient elastography for the diagnosis of liver fibrosis

V. de Lédinghen, J. Vergniol, 2010, Expert review of medical devices.

Anti-inflammatory drugs and variceal bleeding: a case-control study

V. de Lédinghen, D. Heresbach, P. Ingrand, 1999, Gut.

Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study.

V. de Lédinghen, T. Barrioz, P. Ingrand, 1996, Journal of hepatology.

Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis.

M. Ziol, V. de Lédinghen, S. Mueller, 2018, The lancet. Gastroenterology & hepatology.

Liver Stiffness Measurement in Children Using FibroScan: Feasibility Study and Comparison With Fibrotest, Aspartate Transaminase to Platelets Ratio Index, and Liver Biopsy

V. de Lédinghen, L. Sandrin, B. le Bail, 2007, Journal of pediatric gastroenterology and nutrition.

Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

V. de Lédinghen, H. Gin, V. Rigalleau, 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years).

V. de Lédinghen, P. Couzigou, H. Fleury, 2007, Journal of hepatology.

Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.

V. de Lédinghen, T. Asselah, D. Thabut, 2020, Journal of hepatology.

Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study

V. de Lédinghen, A. de Gottardi, L. Rubbia‐Brandt, 2019, Hepatology.

Aiming at minimal invasiveness as a therapeutic strategy for Budd‐Chiari syndrome

V. de Lédinghen, V. Vilgrain, C. Chagneau, 2006, Hepatology.

Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase.

V. de Lédinghen, C. Balabaud, P. Bioulac-Sage, 1999, Journal of hepatology.

Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort

V. de Lédinghen, F. Zoulim, D. Ouzan, 2018, Antiviral therapy.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF NON-ALCOHOLIC FATTY LIVER DISEASE.

V. de Lédinghen, N. Ganne-Carrié, C. Bureau, 2021, Clinics and research in hepatology and gastroenterology.

Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.

V. de Lédinghen, F. Nevens, P. Bedossa, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.

V. de Lédinghen, C. Cassinotto, J. Vergniol, 2014, Journal of hepatology.

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

V. de Lédinghen, J. Bastard, P. Sogni, 2011, Journal of hepatology.

A Placebo‐Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

V. de Lédinghen, P. Potier, F. Zoulim, 2018, The New England journal of medicine.

Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

V. de Lédinghen, J. Zucman‐Rossi, T. Asselah, 2022, Journal of Cannabis Research.

Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference

V. de Lédinghen, Y. Ngo, H. Perazzo, 2018, European journal of gastroenterology & hepatology.

A protective role for CD154 in hepatic steatosis in mice

V. de Lédinghen, E. Chevet, S. Lepreux, 2010, Hepatology.

Long‐term prognosis of patients with metabolic (dysfunction)‐associated fatty liver disease by non‐invasive methods

V. de Lédinghen, D. Dutartre, J. Foucher, 2022, Alimentary pharmacology & therapeutics.

Hepatic Steatosis, Carbohydrate Intake, and Food Quotient in Patients with NAFLD

V. de Lédinghen, H. Gin, V. Rigalleau, 2013, International journal of endocrinology.

Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values

V. Wong, V. de Lédinghen, F. Marra, 2017, Hepatology.

Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses.

V. de Lédinghen, D. Valla, F. Passamonti, 2020, Blood advances.

Performance of simple fibrosis scores in non-obese patients with nonalcoholic fatty liver disease.

V. Wong, V. de Lédinghen, B. le Bail, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.

V. de Lédinghen, B. le Bail, C. Bureau, 2019, Journal of hepatology.

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

V. Wong, V. de Lédinghen, G. Sebastiani, 2018, Journal of hepatology.

Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD

V. Wong, V. de Lédinghen, F. Marra, 2017, Alimentary pharmacology & therapeutics.

Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver.

V. de Lédinghen, B. le Bail, J. Saric, 2000, Journal of hepatology.

Premalignant lesions and hepatocellular carcinoma in a non-cirrhotic alcoholic patient with iron overload and normal transferrin saturation.

V. de Lédinghen, B. le Bail, J. Saric, 1999, Journal of hepatology.

Hepatic hydrothorax associated with vitamin a toxicity.

V. de Lédinghen, R. Miksad, I. Fiel, 2002, Journal of clinical gastroenterology.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF CHRONIC INFECTION WITH HEPATITIS C VIRUS.

A. Luciani, V. de Lédinghen, N. Ganne-Carrié, 2021, Clinics and research in hepatology and gastroenterology.

French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long

V. de Lédinghen, A. Rachas, E. Delarocque-Astagneau, 2020, BMC Infectious Diseases.

ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts

V. de Lédinghen, P. Marcellin, S. Chevret, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.

V. Wong, V. de Lédinghen, M. Stepanova, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications

V. de Lédinghen, A. de Gottardi, D. Valla, 2022, American journal of hematology.

Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.

V. de Lédinghen, D. Sautereau, P. Marquet, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons with HIV infection and Compensated Advanced Chronic Liver Disease.

V. de Lédinghen, G. Sebastiani, G. Guaraldi, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease

V. de Lédinghen, W. Meissner, E. Broussolle, 2020, Neurology.

Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR).

V. de Lédinghen, P. Goupille, J. Sibilia, 2019, Joint, bone, spine : revue du rhumatisme.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF RARE GENETIC LIVER DISEASES.

V. de Lédinghen, O. Guillaud, N. Ganne-Carrié, 2021, Clinics and research in hepatology and gastroenterology.

[Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse].

V. de Lédinghen, T. Poynard, V. Ratziu, 2008, Gastroenterologie clinique et biologique.

Inter-platform Variability of Liver Elastography: Pairwise Comparisons of Four Devices.

V. de Lédinghen, B. Guiu, M. Hermida, 2022, Ultrasound in medicine & biology.

Induction of cyclooxygenase-2 by tumor promoters in transformed and cytochrome P450 2E1-expressing hepatocytes.

V. de Lédinghen, M. Czaja, K. Subbaramaiah, 2002, Carcinogenesis.

Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy.

V. de Lédinghen, P. Couzigou, Denis Smith, 2006, Gastroenterologie clinique et biologique.

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study

V. de Lédinghen, D. Neau, P. Morlat, 2019, PloS one.

The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt

V. de Lédinghen, A. Sommet, D. Thabut, 2021, Annals of Internal Medicine.

Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus

V. de Lédinghen, D. Thabut, N. Ganne-Carrié, 2020, World journal of hepatology.

Impact of Preexisting Inflammatory Bowel Disease on the Outcome of Liver Transplantation for Primary Sclerosing Cholangitis

V. de Lédinghen, J. Dumortier, S. Dharancy, 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort

V. de Lédinghen, P. Marcellin, F. Carrat, 2020, Journal of viral hepatitis.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PORTAL HYPERTENSION.

V. de Lédinghen, M. Rudler, D. Thabut, 2021, Clinics and research in hepatology and gastroenterology.

Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment.

V. de Lédinghen, P. Couzigou, P. Marcellin, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Hypervascular nodule in a fibrotic liver overloaded with iron: identification of a premalignant area with preserved liver architecture

V. de Lédinghen, C. Balabaud, P. Bioulac-Sage, 2005, Comparative hepatology.

Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community‐based cohort

V. de Lédinghen, M. Zins, Marie-Aline Charles, 2022, Hepatology.

Liver fibrosis on account of chronic hepatitis C is more severe in HIV‐positive than HIV‐negative patients despite antiretroviral therapy

V. de Lédinghen, V. Soriano, D. Neau, 2008, Journal of viral hepatitis.

[Non-invasive evaluation of liver fibrosis in hepatitis C].

V. de Lédinghen, T. Poynard, É. Rosenthal, 2008, Gastroenterologie clinique et biologique.

On the validity of meta-analyses: exhaustivity must be warranted, exclusion of duplicate patients too.

V. de Lédinghen, R. Thiébaut, J. Asselineau, 2010, Journal of clinical epidemiology.

Prevention of Biliary Stent Occlusion by Ursodeoxycholic Acid plus Norfloxacin

V. de Lédinghen, D. Sautereau, P. Ingrand, 2004, Digestive Diseases and Sciences.

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.

V. de Lédinghen, F. Carrat, F. Nevens, 2022, Journal of hepatology.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY BILIARY CHOLANGITIS.

V. de Lédinghen, P. Potier, N. Ganne-Carrié, 2021, Clinics and research in hepatology and gastroenterology.

Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use

V. de Lédinghen, D. Dutartre, J. Foucher, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?

V. de Lédinghen, D. Samuel, J. Dumortier, 2015, PloS one.

Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.

V. de Lédinghen, S. Pol, N. Kamar, 2018, Kidney international.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY SCLEROSING CHOLANGITIS.

V. de Lédinghen, P. Potier, N. Ganne-Carrié, 2021, Clinics and research in hepatology and gastroenterology.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF VASCULAR LIVER DISEASES.

V. de Lédinghen, M. Ronot, V. Vilgrain, 2021, Clinics and research in hepatology and gastroenterology.

Reply to: "Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FMVCTE algorithm" and to "Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes".

V. de Lédinghen, P. Calès, V. Leroy, 2018, Journal of hepatology.

Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).

V. de Lédinghen, E. Schiff, Y. Ngo, 2014, Journal of hepatology.

Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection

V. de Lédinghen, P. Calès, J. Guéchot, 2013, Annals of Internal Medicine.

Reply:

V. de Lédinghen, P. Marcellin, D. Dhumeaux, 2007 .

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.

M. Ziol, V. de Lédinghen, P. Marcellin, 2017, Gastroenterology.

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

V. de Lédinghen, T. Asselah, D. Thabut, 2021, BMC Infectious Diseases.

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients

M. Ziol, V. de Lédinghen, P. Marcellin, 2018, American heart journal.

Quantitation of Hepatitis C Virus RNA in Plasma and Peripheral Blood Mononuclear Cells of Patients with Chronic Hepatitis Treated with Interferon-α

V. de Lédinghen, P. Couzigou, H. Fleury, 2004, Digestive Diseases and Sciences.

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores

V. Wong, V. de Lédinghen, L. Sandrin, 2022, Journal of hepatology.

Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis

V. de Lédinghen, D. Thabut, R. Moreau, 2007, Hepatology.

The tolerance and efficacy of a postponed retreatment with infliximab in Crohn’s disease primary responders

V. de Lédinghen, E. Chanteloup, D. Laharie, 2009, Alimentary pharmacology & therapeutics.

[Treatment of hepatorenal syndrome].

V. de Lédinghen, 2004, Gastroenterologie clinique et biologique.

Albumin Use in Patients With Cirrhosis in France: Results of the "ALBU-LIVE" Survey: A Case for Better EASL Guidelines Diffusion and/or Revision.

V. de Lédinghen, D. Thabut, C. Bureau, 2017, Journal of clinical gastroenterology.

Lamivudine therapy of chronic hepatitis B in three groups of patients: non transplanted patients, liver recipients, and kidney recipients.

V. de Lédinghen, P. Couzigou, H. Fleury, 2002, Gastroenterologie clinique et biologique.

Sinusoidal obstruction syndrome.

V. de Lédinghen, M. Robin, D. Valla, 2020, Clinics and research in hepatology and gastroenterology.

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

V. de Lédinghen, D. Thabut, X. Forns, 2022, Journal of viral hepatitis.

Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.

V. de Lédinghen, J. Dumortier, F. Durand, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study

V. de Lédinghen, M. Obadia, F. Ory-Magne, 2022, Movement disorders : official journal of the Movement Disorder Society.

Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004.

V. de Lédinghen, P. Couzigou, D. Neau, 2007, Gastroenterologie clinique et biologique.

Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection

V. de Lédinghen, V. Soriano, G. Satta, 2009, Journal of viral hepatitis.

Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C

V. de Lédinghen, Y. Bacq, F. Oberti, 2009, European journal of gastroenterology & hepatology.

Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis

V. de Lédinghen, J. Lazarus, L. Pezzullo, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

V. de Lédinghen, J. Vaillant, T. Poynard, 2012, Clinics and research in hepatology and gastroenterology.

Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

Julien Vergniol, Gilles Le Naour, G. le Naour, 2012, Journal of hepatology.

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.

M. Kumar, V. Wong, V. de Lédinghen, 2017, Journal of hepatology.

Determination of reliability criteria for liver stiffness evaluation by transient elastography

V. de Lédinghen, S. Bertrais, F. Oberti, 2013, Hepatology.

Noninvasive biomarkers in NAFLD and NASH — current progress and future promise

V. de Lédinghen, S. Sookoian, G. Wong, 2018, Nature Reviews Gastroenterology & Hepatology.

Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations

V. de Lédinghen, P. Couzigou, L. Castéra, 2010, Hepatology.

Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.

V. de Lédinghen, P. Marcellin, L. Sandrin, 2010, Ultrasound in medicine & biology.

Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.

V. Wong, V. de Lédinghen, H. Garg, 2021, The lancet. Gastroenterology & hepatology.

Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.

V. Wong, V. de Lédinghen, A. Tuttolomondo, 2017, Journal of hepatology.

Advancing the global public health agenda for NAFLD: a consensus statement

Myeong Jun Song, R. Malekzadeh, V. Wong, 2021, Nature Reviews Gastroenterology & Hepatology.

EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version).

V. de Lédinghen, J. Bamber, G. Ferraioli, 2017, Ultraschall in der Medizin.

Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.

V. de Lédinghen, D. Samuel, J. Dumortier, 2016, Journal of hepatology.

V. Wong, V. de Lédinghen, G. Sebastiani, 2022, Alimentary pharmacology & therapeutics.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION.

V. de Lédinghen, J. Dumortier, N. Ganne-Carrié, 2021, Clinics and research in hepatology and gastroenterology.

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

V. Wong, M. Ziol, V. de Lédinghen, 2021, Gut.

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

Julien Vergniol, Paul Calès, V. de Lédinghen, 2016, Journal of hepatology.

Psychosocial factors associated with perceived disease severity in patients with chronic hepatitis C: relationship with information sources and attentional coping styles.

V. de Lédinghen, P. Couzigou, A. Constant, 2005, Psychosomatics.

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.

C. Trautwein, V. de Lédinghen, G. Gerken, 2012, Journal of hepatology.

Meta-analyses of FibroTest diagnostic value in chronic liver disease

Patrice Cacoub, Fabien Zoulim, Dominique Thabut, 2007, BMC gastroenterology.

Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients

M. Ziol, V. de Lédinghen, P. Marcellin, 2006, Journal of acquired immune deficiency syndromes.

EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)

Ioan Sporea, Simona Bota, Odd Helge Gilja, 2017, Ultraschall in der Medizin - European Journal of Ultrasound.

Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation

V. de Lédinghen, S. Lepreux, N. Kamar, 2013, Transplant infectious disease : an official journal of the Transplantation Society.

Transient elastography and biomarkers for liver fibrosis assessment and follow‐up of inactive hepatitis B carriers

V. de Lédinghen, P. Couzigou, B. le Bail, 2011, Alimentary pharmacology & therapeutics.

Dynamic and Rapid Changes in Viral Quasispecies by Udps in Chronic Hepatitis C Patients Receiving Telaprevir-Based Therapy

V. de Lédinghen, H. Fleury, M. Kann, 2013, Antiviral therapy.

Diagnosis of choledocholithiasis: EUS or magnetic resonance cholangiography? A prospective controlled study.

R. Lecesne, V. de Lédinghen, P. Couzigou, 1999, Gastrointestinal endoscopy.

Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy

V. de Lédinghen, P. Couzigou, H. Fleury, 2004, Journal of medical virology.

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.

Jisoo A. Kwon, V. Wong, F. Tacke, 2022, The lancet. Gastroenterology & hepatology.

Diagnosis of liver fibrosis by transient elastography (FibroScan) and non‐invasive methods in Crohn's disease patients treated with methotrexate

V. de Lédinghen, P. Couzigou, F. Zerbib, 2006, Alimentary pharmacology & therapeutics.

Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations

V. de Lédinghen, P. Couzigou, L. Castéra, 2006, European journal of gastroenterology & hepatology.

Large-Scale Screening of Lipase Acid Deficiency in at Risk Population.

V. de Lédinghen, M. Krempf, D. Ouzan, 2021, Clinica chimica acta; international journal of clinical chemistry.

Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms.

R. Dantzer, V. de Lédinghen, P. Couzigou, 2005, The Journal of clinical psychiatry.

Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C

V. de Lédinghen, P. Couzigou, A. Constant, 2006, Alimentary pharmacology & therapeutics.

Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals

M. Kumar, V. Wong, V. de Lédinghen, 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.

V. de Lédinghen, T. Asselah, F. Carrat, 2020, Clinics and research in hepatology and gastroenterology.

Epidemiological and phylogenetic evidence for patient‐to‐patient hepatitis C virus transmission during sclerotherapy of varicose veins

V. de Lédinghen, P. Couzigou, H. Fleury, 2005, Journal of medical virology.

Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.

V. de Lédinghen, F. Zoulim, D. Ouzan, 2017, Journal of hepatology.

Hepatitis C Virus Genotyping Based on 5′ Noncoding Sequence Analysis (Trugene)

V. de Lédinghen, P. Couzigou, D. Ouzan, 2001, Journal of Clinical Microbiology.

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

V. de Lédinghen, R. Marinho, T. Asselah, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection

V. de Lédinghen, P. Marcellin, F. Roudot-thoraval, 2007, Journal of viral hepatitis.

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

V. de Lédinghen, S. Imbeaud, J. Zucman‐Rossi, 2018, Gastroenterology.

Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.

V. de Lédinghen, V. Paradis, B. Autran, 2020, Journal of hepatology.

FibroScan used in street‐based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study

V. de Lédinghen, J. Foucher, J. Delile, 2009, Journal of viral hepatitis.

Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study

V. de Lédinghen, F. Zerbib, E. Chanteloup, 2011, Alimentary pharmacology & therapeutics.

Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver

V. de Lédinghen, P. Couzigou, P. Bioulac-Sage, 2010, European journal of gastroenterology & hepatology.

Cystic fibrosis and noninvasive liver fibrosis assessment methods in children

V. de Lédinghen, E. Frison, R. Enaud, 2021, Pediatric Research.

Feasibility of liver transient elastography with FibroScan® using a new probe for obese patients

V. de Lédinghen, V. Rigalleau, J. Vergniol, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Liver and spleen elastography using supersonic shear imaging for the non-invasive diagnosis of cirrhosis severity and oesophageal varices.

V. de Lédinghen, F. Laurent, M. Montaudon, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The epidemiology of Budd-Chiari syndrome in France.

V. de Lédinghen, O. Farges, D. Valla, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study

V. de Lédinghen, D. Samuel, J. Dumortier, 2018, Transplantation.

Direct‐acting antiviral agent–based regimen for HCV recurrence after combined liver‐kidney transplantation: Results from the ANRS CO23 CUPILT study

V. de Lédinghen, D. Samuel, J. Dumortier, 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

Julien Vergniol, V. de Lédinghen, P. Couzigou, 2011, Gastroenterology.

Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort

V. de Lédinghen, D. Samuel, F. Durand, 2019, European Journal of Clinical Pharmacology.

V. Wong, V. de Lédinghen, S. Sookoian, 2022, Hepatology.

Gastric variceal bleeding uncovering a rare association of CREST syndrome, primary biliary cirrhosis, nodular regenerative hyperplasia and pulmonary hypertension.

V. de Lédinghen, B. le Bail, J. Vergniol, 2010, European journal of gastroenterology & hepatology.

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Albert Tran, Vincent Leroy, Dominique Larrey, 2018, Gastroenterology.

Early liver transplantation for corticosteroid non-responders in acute severe autoimmune hepatitis: the SURFASA score.

V. de Lédinghen, P. Potier, D. Samuel, 2021, Journal of hepatology.

Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases.

V. de Lédinghen, P. Couzigou, A. Constant, 2006, World journal of gastroenterology.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF AUTOIMMUNE HEPATITIS.

V. de Lédinghen, N. Ganne-Carrié, C. Bureau, 2021, Clinics and research in hepatology and gastroenterology.

Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.

V. de Lédinghen, S. Chevret, S. Pol, 2018, Journal of hepatology.

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis.

M. Ziol, V. de Lédinghen, J. Zucman‐Rossi, 2022, Journal of hepatology.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

V. de Lédinghen, G. Dore, S. Pol, 2015, Gastroenterology.

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials

V. de Lédinghen, M. Burroughs, M. Shiffman, 2021, Journal of viral hepatitis.

MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity.

V. de Lédinghen, F. Laurent, H. Cochet, 2015, European journal of radiology.

[A 1993-1995 epidemiological survey of home parenteral nutrition in approved centers for adults in France].

V. de Lédinghen, X. Leverve, D. Heresbach, 1998, Gastroenterologie clinique et biologique.

Liver stiffness measurements for evaluation of central venous pressure in congenital heart diseases

V. de Lédinghen, T. Barnetche, J. Vergniol, 2015, Heart.

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

V. de Lédinghen, D. Thabut, B. le Bail, 2006, BMC gastroenterology.

Prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin: a multicenter randomized trial.

V. de Lédinghen, D. Sautereau, P. Ingrand, 2000, Digestive diseases and sciences.

Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)

V. de Lédinghen, P. Marcellin, F. Roudot-thoraval, 2015, Gut.

A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients

V. de Lédinghen, H. Cortez‐Pinto, G. Hirschfield, 2021, Expert review of gastroenterology & hepatology.

Hepatitis C virus infection impacts work productivity and fatigue: An epidemiologic real-life study.

V. de Lédinghen, D. Ouzan, D. Larrey, 2019, Annals of hepatology.

FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases

V. de Lédinghen, P. Couzigou, L. Castéra, 2006, Hepatology.

French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes.

V. de Lédinghen, T. Asselah, M. Stepanova, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Relationship between the severity of hepatitis C virus-related liver disease and the presence of Helicobacter species in the liver: a prospective study.

F. Mégraud, V. de Lédinghen, P. Couzigou, 2006, World journal of gastroenterology.

[Proctitis after colonoscopy: importance of rinsing the colonoscope!].

V. de Lédinghen, T. Barrioz, P. Babin, 1996, Gastroenterologie clinique et biologique.

Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

V. de Lédinghen, P. Couzigou, A. Alberti, 2010, Journal of hepatology.

Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study.

V. de Lédinghen, P. Couzigou, L. Castéra, 2008, Gastroenterologie clinique et biologique.

Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

Julien Vergniol, V. de Lédinghen, B. le Bail, 2013, Radiology.

Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients

R. Lecesne, V. de Lédinghen, P. Couzigou, 2002, European journal of gastroenterology & hepatology.

Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C

Gérard Forzy, Julien Vergniol, Laurent Castera, 2009, Hepatology.

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

Dominique Thabut, Mohamed Tahiri, V. de Lédinghen, 2006, BMC gastroenterology.

Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study

V. de Lédinghen, J. Pawlotsky, F. Zoulim, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV

V. de Lédinghen, D. Thabut, F. Carrat, 2021, JHEP reports : innovation in hepatology.

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement

M. Kumar, V. Wong, V. de Lédinghen, 2018, Alimentary pharmacology & therapeutics.

Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe.

V. de Lédinghen, K. Leung, H. Chan, 2013, Annals of hepatology.

Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®.

V. Wong, V. de Lédinghen, H. Chan, 2012, Journal of hepatology.

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

V. de Lédinghen, P. Marcellin, E. Letouzé, 2018, Hepatology.

Paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome: therapeutic challenge with bone marrow transplantation, transjugular intrahepatic portosystemic shunt, and vena cava stent.

V. de Lédinghen, P. Couzigou, J. Vergniol, 2005, European journal of gastroenterology & hepatology.

[Cyclooxygenase inhibitors].

V. de Lédinghen, G. Dalbagni, B. Weksler, 2001, Presse medicale.

Impact of type 2 diabetes on the accuracy of non-invasive tests of liver fibrosis with resulting clinical implications.

V. de Lédinghen, B. le Bail, C. Canivet, 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD

V. de Lédinghen, C. Canivet, T. Decaens, 2022, Hepatology.

A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.

V. de Lédinghen, S. Bertrais, R. Anty, 2017, Journal of hepatology.

An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.

V. de Lédinghen, M. Friedrich-Rust, F. Carrat, 2015, Journal of hepatology.

Reliability Criteria of Two-Dimensional Shear Wave Elastography: Analysis of 4277 Measurements in 788 Patients.

V. de Lédinghen, M. Ronot, V. Paradis, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Criteria to Determine Reliability of Noninvasive Assessment of Liver Fibrosis With Virtual Touch Quantification

V. de Lédinghen, B. le Bail, G. Hunault, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.

V. de Lédinghen, N. Mikhail, F. Carrat, 2022, Clinics and research in hepatology and gastroenterology.

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

V. de Lédinghen, F. Zoulim, D. Guyader, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease.

M. Ziol, V. de Lédinghen, P. Marcellin, 2008, Journal of hepatology.

Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages.

V. de Lédinghen, L. Castéra, P. Halfon, 2007, Clinical chemistry.

FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

V. de Lédinghen, D. Thabut, T. Poynard, 2011, Clinics and research in hepatology and gastroenterology.

Non-invasive evaluation of liver fibrosis using FibroScan in long-term sustained-virological responder patients after HCV treatment.

V. de Lédinghen, P. Couzigou, L. Castéra, 2008, Gastroenterologie clinique et biologique.

Changes of non‐invasive markers and FibroScan values during HCV treatment

V. de Lédinghen, P. Couzigou, L. Castéra, 2009, Journal of viral hepatitis.

Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial.

V. de Lédinghen, R. Amathieu, M. Rudler, 2015, Journal of hepatology.

Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients

V. de Lédinghen, P. Morlat, F. Bonnet, 2014, BMC Infectious Diseases.

Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C

V. de Lédinghen, P. Couzigou, D. Breilh, 2009, Alimentary pharmacology & therapeutics.

[Hepatocellular carcinoma in the non-cirrhotic liver: renewed interest].

V. de Lédinghen, B. le Bail, C. Balabaud, 1998, Gastroentérologie Clinique et Biologique.

[Vascular pathology of the portal vein distal branches: a rare cause of liver transplantation and a protean clinical presentation].

V. de Lédinghen, B. le Bail, J. Saric, 2000, Gastroenterologie clinique et biologique.

[Nodular regenerative hyperplasia of the liver and Turner syndrome].

V. de Lédinghen, L. Palazzo, M. Fabre, 1994, Gastroentérologie Clinique et Biologique.

Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

V. de Lédinghen, J. Zucman‐Rossi, M. Ronot, 2021, JHEP reports : innovation in hepatology.

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)

V. de Lédinghen, P. Marcellin, S. Chevret, 2015, Hepatology.

Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?

V. de Lédinghen, D. Samuel, R. Anty, 2022, Viruses.

Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease

V. Wong, V. de Lédinghen, H. Chan, 2019, Gut.

Diagnosis and management of hepatic encephalopathy: The French recommendations

V. de Lédinghen, D. Galanaud, M. Rudler, 2023, Liver international : official journal of the International Association for the Study of the Liver.

Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance

V. de Lédinghen, T. Asselah, D. Thabut, 2021, JHEP Reports.

Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries.

F. Tacke, V. de Lédinghen, M. Buti, 2023, Journal of hepatology.

2D-shear wave elastography: number of acquisitions can be reduced according to clinical setting

V. de Lédinghen, G. Chatellier, C. Strassburg, 2021, Insights into Imaging.

Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.

M. Ziol, V. de Lédinghen, P. Marcellin, 2015, Annals of hepatology.

Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy

Xavier Forns, V. de Lédinghen, X. Forns, 2012, PloS one.

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C

M. Ziol, V. de Lédinghen, P. Marcellin, 2012, Journal of viral hepatitis.

Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation

V. de Lédinghen, V. Soriano, C. Quereda, 2009, Antiviral therapy.

The SLC40A1 R178Q mutation is a recurrent cause of hemochromatosis and is associated with a novel pathogenic mechanism

V. de Lédinghen, C. Ged, C. Oudin, 2018, Haematologica.

QUALITY CRITERIA FOR THE MEASUREMENT OF LIVER STIFFNESS.

V. de Lédinghen, N. Ganne-Carrié, C. Bureau, 2021, Clinics And Research in Hepatology and Gastroenterology.

Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015

V. de Lédinghen, E. Delarocque-Astagneau, C. Brouard, 2017, BMC Infectious Diseases.

Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!

V. de Lédinghen, G. Hunault, F. Oberti, 2019, Clinical and translational gastroenterology.

Eight Weeks Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.

V. de Lédinghen, F. Nevens, J. Dillon, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

V. de Lédinghen, S. Petta, V. Wong, 2017, Hepatology.

Hepatic steatosis in HIV‐HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype

V. de Lédinghen, D. Neau, F. Dabis, 2007, Alimentary pharmacology & therapeutics.

Cirrhosis Diagnosis and Liver Fibrosis Staging: Transient Elastometry Versus Cirrhosis Blood Test

V. de Lédinghen, F. Oberti, P. Calès, 2014, Journal of clinical gastroenterology.

Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis

V. de Lédinghen, M. Chevallier, S. Pol, 2004, European journal of gastroenterology & hepatology.

Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

L. N. Valenti, V. de Lédinghen, G. Sebastiani, 2023, JHEP reports : innovation in hepatology.

Individual and population screening of varices needing treatment by a simple, safe and accurate test.

V. de Lédinghen, P. Nahon, N. Ganne-Carrié, 2023, Clinics and research in hepatology and gastroenterology.

Agreement Between 2-dimensional Shear Wave and Transient Elastography Values for Diagnosis of Advanced Chronic Liver Disease.

V. de Lédinghen, N. Molinari, B. Guiu, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Impact of Surgery and Valvuloplasty on Liver Stiffness in a Patient With Pericarditis and Pulmonary Valvulopathy

V. de Lédinghen, J. Thambo, X. Iriart, 2017, World journal for pediatric & congenital heart surgery.

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.

V. Wong, V. de Lédinghen, P. Bossuyt, 2023, The lancet. Gastroenterology & hepatology.

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes

V. Wong, V. de Lédinghen, R. Stauber, 2023, Hepatology.

Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

V. de Lédinghen, M. Buti, T. Berg, 2023, JHEP reports : innovation in hepatology.

Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort

V. de Lédinghen, F. Zoulim, J. Dumortier, 2022, Journal of Hepatology.

HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management

V. de Lédinghen, T. Asselah, F. Zoulim, 2021, Cancer Prevention Research.

Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings

V. de Lédinghen, T. Asselah, X. Causse, 2022, Journal of Hepatology.

Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)

V. de Lédinghen, M. Zins, S. Kab, 2023, Hepatology.

The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries

V. de Lédinghen, V. Atella, A. Torbica, 2020, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY MALIGNANT LIVER TUMOURS.

A. Luciani, M. Soussan, V. de Lédinghen, 2021, Clinics and research in hepatology and gastroenterology.

Effects of Helicobacter pylori infection on gut appetite peptide (leptin, ghrelin) expression in elderly inpatients.

F. Mégraud, V. de Lédinghen, J. Emeriau, 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[Partial regression of a desmoid tumor after prolonged treatment with lanreotide].

V. de Lédinghen, T. Barrioz, P. Beau, 1995, Gastroenterologie clinique et biologique.

[Treatment of hepatorenal syndrome].

V. de Lédinghen, Victor de Lédinghen, 2004, Gastroenterologie clinique et biologique.

Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.

V. de Lédinghen, R. Anty, C. Bureau, 2023, Journal of hepatology.

Ribavirin posology, observance, and sustained virologic response.

V. de Lédinghen, P. Couzigou, L. Castéra, 2008, Clinical Gastroenterology and Hepatology.

Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests

V. de Lédinghen, M. Friedrich-Rust, F. Carrat, 2015, Clinical chemistry and laboratory medicine.

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF HYPERFERRITINAEMIA.

V. de Lédinghen, H. Hamdi-Rozé, N. Ganne-Carrié, 2021, Clinics and research in hepatology and gastroenterology.

The NAFLD burden on mortality and morbidities in general population: A community‐based longitudinal study (NASH‐CO study)

V. de Lédinghen, M. Zins, S. Kab, 2023, Liver international : official journal of the International Association for the Study of the Liver.

Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications

V. de Lédinghen, A. de Gottardi, D. Valla, 2022 .

Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

V. de Lédinghen, Y. Yazdanpanah, D. Neau, 2018, HIV medicine.

A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C

V. de Lédinghen, S. Bertrais, F. Oberti, 2017 .

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.

M. Manns, V. de Lédinghen, M. Buti, 2017, The lancet. Gastroenterology & hepatology.

Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests

V. de Lédinghen, V. Paradis, P. Bedossa, 2023, Nature communications.

G. le Naour, V. de Lédinghen, J. Vaillant, 2012, Journal of hepatology.

Determination of reliability criteria for liver stiffness evaluation by transient elastography

V. de Lédinghen, S. Bertrais, F. Oberti, 2013, Hepatology.

Feasibility of liver transient elastography with FibroScan® using a new probe for obese patients

V. de Lédinghen, V. Rigalleau, J. Vergniol, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.

Jisoo A. Kwon, R. Malekzadeh, F. Tacke, 2023, The lancet. Gastroenterology & hepatology.

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

David C. Jones, V. de Lédinghen, F. Carrat, 2023, Hepatology.

Sofosbuvir‐based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)

V. de Lédinghen, P. Marcellin, S. Chevret, 2015, Hepatology.

Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort

V. de Lédinghen, D. Samuel, F. Durand, 2019, European Journal of Clinical Pharmacology.

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes

V. Wong, V. de Lédinghen, R. Stauber, 2023, Hepatology.

Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort)

V. de Lédinghen, J. Zucman‐Rossi, D. Thabut, 2023, Quality of Life Research.

EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)

V. de Lédinghen, J. Bamber, G. Ferraioli, 2017, Ultraschall in der Medizin - European Journal of Ultrasound.

Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study

V. de Lédinghen, D. Neau, S. Pédeboscq, 2023, Scientific reports.

[Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse].

V. de Lédinghen, T. Poynard, V. Ratziu, 2008, Gastroenterologie clinique et biologique.

Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.

V. de Lédinghen, D. Samuel, J. Dumortier, 2016, Journal of hepatology.

Treatment With Bulevirtide in HIV Infected patients With chronic Hepatitis Delta. ANRS HD EP01 BULEDELTA & Compassionate Cohort

V. de Lédinghen, O. Chazouilleres, C. Gaudy-Graffin, 2024, JHEP Reports.

Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy: the retrospective multicenter European study (Save-D)

V. de Lédinghen, A. Mangia, X. Causse, 2023, Journal of Hepatology.

HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort

V. de Lédinghen, T. Asselah, X. Causse, 2023, Journal of Hepatology.

The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories.

V. de Lédinghen, R. Idilman, C. Yurdaydın, 2023, Journal of hepatology.

AGILE SCORES IN MASLD AND ALD: EXTERNAL VALIDATION AND THEIR UTILITY IN CLINICAL ALGORITHMS.

V. de Lédinghen, M. Thiele, O. Elshaarawy, 2024, Journal of Hepatology.

Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.

V. de Lédinghen, Wen-Yue Liu, G. Goh, 2024, JAMA.

Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors

V. de Lédinghen, D. Roulot, R. Borie, 2023, Hepatology.

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.

C. Datz, V. de Lédinghen, E. Cholongitas, 2024, Hepatology international.